27 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Article Searches
Corcept Therapeutics plunges after loss in patent battle with with Teva https://seekingalpha.com/news/4051439-corcept-therapeutics-plunges-after-loss-in-patent-battle-with-with-teva?source=feed_sector_healthcare Jan 01, 2024 - Corcept Therapeutics (CORT) tumbles 38% in after-hours trading following a patent trial loss to Teva (TEVA) over its Cushing's syndrome drug, Korlym.
Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva https://www.zacks.com/stock/news/2204522/corcept-cort-falls-on-loss-of-korlym-patent-lawsuit-to-teva?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2204522 Jan 02, 2024 - The United States district court for the district of New Jersey rules against Corcept (CORT) in a patent infringement lawsuit against Teva Pharmaceuticals. Stock declines.
Teva raised to Buy at Jefferies citing a positive setup ahead of 2024 outlook https://seekingalpha.com/news/4057313-teva-stock-raised-buy-jefferies?source=feed_tag_israel Jan 23, 2024 - Jefferies upgrades Teva Pharmaceutical (TEVA) to Buy from Hold ahead of the company's 2024 outlook citing multiple tailwinds to its business. Read more here.
Unveiling Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Outlook: Wall Street Estimates for Key Metrics https://www.zacks.com/stock/news/2216435/unveiling-teva-pharmaceutical-industries-ltd-teva-q4-outlook-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2216435 Jan 26, 2024 - Besides Wall Street's top -and-bottom-line estimates for Teva Pharmaceutical Industries Ltd. (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs https://www.cnbc.com/2024/01/28/big-pharma-merck-bristol-myers-jj-prepare-to-lose-revenue.html Jan 28, 2024 - Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.
Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates https://www.zacks.com/stock/news/2218858/teva-pharmaceutical-industries-ltd-teva-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2218858 Jan 31, 2024 - Although the revenue and EPS for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teva upgraded to Overweight at Piper Sandler on multiple expansion https://seekingalpha.com/news/4065532-teva-stock-upgraded-piper-sandler-valuation?source=feed_tag_israel Feb 12, 2024 - Piper Sandler upgraded Teva Pharmaceutical (TEVA) to Overweight and raised its price target to $19 from $12 per share citing valuation. Read more here.
Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Position https://seekingalpha.com/article/4670634-teva-pharmaceutical-i-need-to-see-growth-before-starting-a-position?source=feed_tag_israel Feb 15, 2024 - Teva Pharmaceutical's weak financial performance, declining revenues, and industry uncertainties make it a risky investment. Read why I rate TEVA stock a hold.
Teva and Jiangsu announce partnership for distribution of AUSTEDO in China https://seekingalpha.com/news/4071489-teva-and-jiangsu-announce-partnership-for-distribution-of-austedo-in-china?source=feed_tag_israel Feb 26, 2024 - Teva Pharmaceutical and Jiangsu Nhwa forge a strategic partnership to enhance patient access to AUSTEDO, a drug for neurodegenerative and movement...
Teva Pharmaceutical Industries: Potential Outweighs Concerns https://seekingalpha.com/article/4680308-teva-pharmaceutical-industries-potential-outweighs-concerns?source=feed_tag_israel Mar 25, 2024 - Teva Pharmaceutical is deeply undervalued, trading at a 77% discount per my calculations. The new CEO's turnaround plan looks promising. Find out why TEVA stock is a Buy.

Pages: 123

Page 1>